Plain-English translation of NCT07640191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called the iVEAcare Neuromodulation System for people with drug-resistant epilepsy — epilepsy that doesn't respond well to anti-seizure medications. The device is surgically implanted and works by stimulating the vagus nerve, a major nerve in your body that connects to your brain. Researchers want to see if this device can safely reduce how often and how severe your seizures are, and whether it improves your quality of life.
Many people with epilepsy continue to have seizures even after trying multiple medications. This trial exists to explore whether this new nerve-stimulation treatment could offer another option for people whose seizures aren't controlled by drugs alone.
You likely qualify if…
You likely don't qualify if…
You would undergo surgery to have the iVEAcare device implanted. After surgery, you'll visit the clinic at 1 month, 3 months, 6 months, 1 year, 18 months, and then yearly through 5 years. At each visit, you'll answer questions about your seizures and how the treatment is affecting your daily life. Between visits, you'll keep a daily diary of any seizures you experience. Your current anti-seizure medications will stay the same throughout at least the first 6 months of the study.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
Australia